28 Chapter 1 STROKEAHA.111.000544 88. Montagne A, et al. Ultra-sensitive molecular MRI of cerebrovascular cell activation enables early detection of chronic central nervous system disorders. Neuroimage. Nov 1 2012;63(2):760-70. doi:10.1016/j.neuroimage.2012.07.018 89. Chen JW, et al. Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. Brain. Apr 2008;131(Pt 4):1123-33. doi:10.1093/ brain/awn004 90. Breckwoldt MO, et al. Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc Natl Acad Sci U S A. Nov 25 2008;105(47):18584-9. doi:10.1073/ pnas.0803945105 91. Costa GL, et al. Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit. J Immunol. Aug 15 2001;167(4):2379-87. doi:10.4049/ jimmunol.167.4.2379 92. Barrera P, et al. Radiolabelled interleukin-1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford). Aug 2000;39(8):870-4. doi:10.1093/ rheumatology/39.8.870 93. Frullano L, et al. A myelin-specific contrast agent for magnetic resonance imaging of myelination. J Am Chem Soc. Feb 16 2011;133(6):1611-3. doi:10.1021/ja1040896 94. Wang C, et al. Longitudinal near-infrared imaging of myelination. J Neurosci. Feb 16 2011;31(7):238290. doi:10.1523/JNEUROSCI.2698-10.2011 95. Datta G, et al. Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis. Mult Scler. Oct 2017;23(11):1469-1478. doi:10.1177/1352458516681504 96. Oh U, et al. Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol. Sep 2011;6(3):354-61. doi:10.1007/ s11481-010-9243-6 97. Rissanen E, et al. In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand (1) (1)C-PK11195. J Nucl Med. Jun 2014;55(6):939-44. doi:10.2967/jnumed.113.131698 98. Versijpt J, et al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. Mult Scler. Apr 2005;11(2):127-34. doi:10.1191/1352458505ms1140oa 99. Vowinckel E, et al. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. Journal of Neuroscience Research. Oct 15 1997;50(2):345-353. doi:Doi 10.1002/(Sici)10974547(19971015)50:2<345::Aid-Jnr22>3.0.Co;2-5 100.Guilarte TR. TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward. Pharmacol Ther. Feb 2019;194:44-58. doi:10.1016/j.pharmthera.2018.09.003 101. Edison P, et al. Microglia, amyloid, and cognition in Alzheimer’s disease: An [11C](R)PK11195PET and [11C]PIB-PET study. Neurobiol Dis. Dec 2008;32(3):412-9. doi:10.1016/j.nbd.2008.08.001 102. Yasuno F, et al. Increased binding of peripheral benzodiazepine receptor in Alzheimer’s disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry. Nov 15 2008;64(10):835-41. doi:10.1016/j. biopsych.2008.04.021 103.Ouchi Y, et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol. Feb 2005;57(2):168-75. doi:10.1002/ ana.20338 104. BanatiRB, et al. [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen’s encephalitis. Neurology. Dec 10 1999;53(9):2199-203. doi:10.1212/wnl.53.9.2199 105. Cagnin A, et al. In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain. Oct 2001;124(Pt 10):2014-27. doi:10.1093/ brain/124.10.2014 106. Turner MR, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. Apr 2004;15(3):601-9. doi:10.1016/j.nbd.2003.12.012 107.Messmer K, et al. Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington’s disease. Neurosci Lett. Jan 23 1998;241(1):53-6. doi:10.1016/s03043940(97)00967-1 108. Cagnin A, et al. In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol. Dec 2004;56(6):894-7. doi:10.1002/ana.20332 109. Banati RB, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain. Nov 2000;123 ( Pt 11)(11):2321-37. doi:10.1093/brain/123.11.2321 110. Venneti S, et al. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol. Dec 2006;80(6):308-22. doi:10.1016/j. pneurobio.2006.10.002 111. Colasanti A, et al. In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with (18) F-PBR111 PET. J Nucl Med. Jul 2014;55(7):1112-8. doi:10.2967/jnumed.113.135129 112. Debruyne JC, et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol. May 2003;10(3):257-64. doi:10.1046/
RkJQdWJsaXNoZXIy MTk4NDMw